<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00918567</url>
  </required_header>
  <id_info>
    <org_study_id>B4Z-US-X053</org_study_id>
    <nct_id>NCT00918567</nct_id>
  </id_info>
  <brief_title>Impact of Strattera and Behavior Therapy on the Home and School Functioning of Children With ADHD</brief_title>
  <official_title>Effects of Strattera and Behavior Therapy on the School and Home Functioning of Elementary School Children With Attention-Deficit/Hyperactivity Disorder (ADHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>State University of New York at Buffalo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Multiple studies have found Atomoxetine (Strattera) to be efficacious but there
      is only one published study specifically designed to evaluate its efficacy in school
      settings. In this 7 week placebo-controlled study, Atomoxetine (ATX) at mean dose of 1.3
      mg/kg, significantly reduced teacher rated ADHD symptoms (Weiss et al., 2005). However,
      children are typically referred for treatment because of &quot;real life&quot; problems in functioning,
      not symptoms (Pelham, Fabiano, &amp; Massetti, 2005). While ATX has been found to produce
      functional improvements at home, the Weiss study found limited results in this area at
      school.

      Furthermore, almost no research has examined the effects of combining ATX and behavior
      therapy (BT). In the MTA, adding BT to stimulants improved teacher ratings of
      hyperactivity/impulsivity and increased the number of subjects reaching optimal response
      (Swanson et al., 2001). Therefore, it is possible that the addition of BT to ATX may improve
      functional performance in the classroom. The effects of combined therapy may be even larger
      for ATX as monotherapy with nonstimulants produces smaller effect sizes than with stimulants.

      Objective: The primary objective was to evaluate the effects of ATX alone and in combination
      with BT on the school functioning of 56 children ages 6-12 with ADHD. Outcomes were assessed
      using traditional symptoms measures as well as functional measures of academic and behavioral
      improvements in the classroom.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives were evaluated in an 8 week open label trial of where half of the participants
      were randomly assigned to receive (ATX+BT) while the rest received only ATX. An open label
      design was employed as the efficacy of ATX for ADHD symptoms has been established and to
      ensure that all patients received at least one active treatment. Parents in the ATX+BT group
      attended an eight week parenting course using the Community Oriented Parent Education (COPE)
      program (Cunningham, Bremner, &amp; Secord, 1998) while the child participated in an eight week
      social skills course. Teachers implemented a Daily Report Card (DRC) to track classroom
      behaviors. In the BT group, the child's DRC performance was communicated daily to parents and
      tied to consequences at home and school. In the ATX group, parents were not provided with the
      DRCs. The ATX dosing protocol was as follows: .5mg/kg per day on days 1-3, .8mg/kg/day days
      4-7, 1.2mg/kg days 8+. After 3 weeks, subjects were eligible to increase to 1.8mg/kg/day. ATX
      was dosed once in the morning but could be dosed BID to address tolerability. The mean final
      dose was 1.4mg/kg/day.

      To be enrolled, children must have had an IQ &gt; 75, not failed a trial of ATX, met DSM
      criteria for ADHD but not other psychiatric comorbidities except ODD/CD and be in good
      physical health. Children already taking ADHD medication were enrolled only if the average
      symptom score on the ADHD subscale of the Disruptive Behaviors Disorders (DBD) scale was &gt;2
      (moderate impairment). ADHD was confirmed by parent report on the DISC and the DBD, which
      rates all DSM 3R and IV symptoms of ODD, CD and ODD on a 0-3 likert scale. Subjects were also
      required to evidence ADHD symptoms in the classroom as rated on the IOWA Conners. Psychiatric
      comorbidities were assessed using the DISC.

      Measures of treatment response included:

        1. Parents and teacher ratings on the IOWA Conners: 10 item Likert ratings to measure
           children's inattention-overactive-impulsive and oppositional-defiant behavior (Milich,
           Loney, &amp; Landau, 1982)

        2. Parent and teacher ratings on the Impairment Rating Scale (IRS): 8 items using
           visual-analogue scales to measure children's functional impairment in peer
           relationships, adult-child relationships, academic performance, classroom behavior, and
           self esteem (Fabiano et al., 2006).

        3. Parent and teacher side effect ratings using a structured list of common side effects
           seen with ATX modeled after the Pittsburgh Side Effects Rating Scale (Pelham, 1993).

        4. Direct observations of subjects to measure rule violations and on/off task behavior
           using a modified version of the COCADD system (Atkins, Pelham &amp; Licht, 1988) in which
           trained observers watched children in their classroom for 30 minutes, recording each
           rule violation and off-task behavior.

        5. Parent and teacher rating on the Social Skills Rating Scale (SSRS): a measure of
           teachers' and parents perceptions of children's social and academic skills and of their
           overall problem behaviors (Gresham &amp; Elliott, 1990).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rule Violations During Direct Classroom Observation at Endpoint (Week 8)</measure>
    <time_frame>Endpoint (Week 8)</time_frame>
    <description>Observations were conducted using the Student Behavior Teacher Response Observation Code. After learning the classroom rules, observers watched children in their classrooms for 30 minutes during an academic activity and recorded each time the subject violated a classroom rule. Total classroom rule violations were used as the primary outcome measures for the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impairment Rating Scale (Parent Completed) at Endpoint</measure>
    <time_frame>Endpoint (Week 8)</time_frame>
    <description>The IRS is a 8 item measure that uses visual-analogue scales to evaluate the child's problem level and need for treatment in developmentally important areas, such as peer relationships, adult-child relationships, academic performance, and classroom behavior 51. The scale is scored from 0 (no problem) to 6 (extreme problem). The scale has excellent test-retest and inter-rater reliability and well supported validity 51, 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impairment Rating Scale (Teachers) at Endpoint</measure>
    <time_frame>Endpoint (Week 8)</time_frame>
    <description>The IRS is a 6 item measure that uses visual-analogue scales to evaluate the child's problem level and need for treatment in developmentally important areas, such as peer relationships, adult-child relationships, academic performance, and classroom behavior. The scale is scored from 0 (no problem) to 6 (extreme problem). The scale has excellent test-retest and inter-rater reliability and well supported validity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Side Effects Rating Scale (PSERS)(Parent Completed) at Endpoint:</measure>
    <time_frame>Endpoint (Week 8)</time_frame>
    <description>The PSERS measures adverse events commonly associated with stimulant medication and has been used in multiple studies of ADHD. For this study, the PSERS was modified to also assess adverse emotional events potentially associated with ATX, including suicidal statements. The resulting scale consisted of 14 items (an additional sleep item for parents) rated from 0 (&quot;none&quot;) to 3 (&quot;severe&quot;). An overall side effects score was computed by averaging across all ratings and used in analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Side Effects Rating Scale (PSERS)(Teacher Rated):</measure>
    <time_frame>at weeks 8 (Endpoint)</time_frame>
    <description>The PSERS measures adverse events commonly associated with stimulant medication and has been used in multiple studies of ADHD. For this study, the PSERS was modified to also assess adverse emotional events potentially associated with ATX, including suicidal statements. The resulting scale consisted of 13 items (for teachers) rated from 0 (&quot;none&quot;) to 3 (&quot;severe&quot;). An overall side effects score was computed by averaging across all ratings and used in analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disruptive Behavior Disorders Rating Scale ODD Subscale (DBD- Parent Completed) at Endpoint</measure>
    <time_frame>Endpoint (Week 8)</time_frame>
    <description>The DBD consists of 8 items that are the DSM-IV symptoms of Oppositional Defiant Disorder (ODD). Items on the DBD were rated by parents and teachers using Likert scales that ranged from 0 (&quot;not at all&quot;) to 3 (&quot;very much&quot;). The factor structure, reliability and validity of the DBD have been supported in multiple studies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disruptive Behavior Disorder Rating Scale ODD Subscale(DBD- Teacher Completed) at Endpoint</measure>
    <time_frame>Endpoint (Week 8)</time_frame>
    <description>The DBD consists of 8 items that are the DSM-IV symptoms of Oppositional Defiant Disorder (ODD). Items on the DBD were rated by parents and teachers using Likert scales that ranged from 0 (&quot;not at all&quot;) to 3 (&quot;very much&quot;). The factor structure, reliability and validity of the DBD have been supported in multiple studies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Skills Rating Scale Problem Behavior Subscale(SSRS Parent) at Endpoint</measure>
    <time_frame>Endpoint (Week 8)</time_frame>
    <description>completed by parents to measure children's problem behaviors (PB). Items are rated from 0 (&quot;not at all&quot;) to 2 (&quot;very often&quot;). The scale has 55 items. The score reported below is the sum total of the items on the scale and then averaged for the whole group. Therefore, the range can be between 0 and 110. A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Skills Rating Scale Problem Behavior Subscale(SSRS Teachers) at Endpoint</measure>
    <time_frame>Endpoint (Week 8)</time_frame>
    <description>The SSRS was completed by teachers to measure children's problem behaviors (PB). Items are rated from 0 (&quot;not at all&quot;) to 2 (&quot;very often&quot;). The scale has 55 items. The score reported below is the sum total of the items on the scale and then averaged for the whole group. Therefore, the range can be between 0 and 110. A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADHD Subscale of the DBD (Parent Completed) at Endpoint</measure>
    <time_frame>Endpoint (Week 8)</time_frame>
    <description>The DBD consists of 18 items that are the DSM-IV symptoms of ADHD. Items on the DBD were rated by parents and teachers using Likert scales that ranged from 0 (&quot;not at all&quot;) to 3 (&quot;very much&quot;). The factor structure, reliability and validity of the DBD have been supported in multiple studies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADHD Subscale of the DBD (Teacher Completed) at Endpoint</measure>
    <time_frame>Endpoint (Week 8)</time_frame>
    <description>The ADHD subscale of the DBD consists of 18 items that are the DSM-IV symptoms of ADHD. Items on the DBD were rated by parents and teachers using Likert scales that ranged from 0 (&quot;not at all&quot;) to 3 (&quot;very much&quot;). The factor structure, reliability and validity of the DBD have been supported in multiple studies.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Combined therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>atomoxetine plus behavior therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>atomoxetine alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atomoxetine</intervention_name>
    <description>open label treatment dosed up to 1.8mg/kg/day</description>
    <arm_group_label>Combined therapy</arm_group_label>
    <arm_group_label>Drug therapy</arm_group_label>
    <other_name>Drug Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavior Modification Therapy</intervention_name>
    <description>8 week behavioral modification course with school consultation, parenting groups using COPE and child social skills group</description>
    <arm_group_label>Combined therapy</arm_group_label>
    <other_name>Behavior Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. meet DSM-IV diagnostic criteria for ADHD-combined type;

          2. estimated IQ of 75 or higher;

          3. agree to comply with the randomly assigned treatment condition;

          4. enrolled in full time school at first grade level or higher; AND

          5. have a primary teacher available to complete ratings for the entire study duration.

        Exclusion Criteria:

          1. current or past history of seizures (not including benign febrile seizures) or other
             neurological disorders;

          2. physical conditions that preclude administration of Strattera or other medical illness
             that might confound study results or increase the safety risk to subjects exposed to
             study treatments (i.e. marked cardiac conduction delay, etc.);

          3. prior failed trial of Strattera defined as 3 weeks or more on a daily dose of
             Strattera of at least .8mg/kg or a documented inability to tolerate at least
             .8mg/kg/day;

          4. serious forms of psychopathology other than ADHD, such autism, bipolar disorder,
             schizophrenia or any other psychopathology requiring urgent treatment with
             psychotropic medication; OR

          5. children for whom discontinuation of their current psychotropic medication would
             represent a serious risk to themselves or others.

        The presence of Oppositional Defiant Disorder (ODD), Conduct Disorder (CD) or learning
        disabilities will not result in exclusion from the study as they are commonly occurring
        comorbidities that have not been found to moderate response to ADHD treatments (Jensen et
        al., 2001). Enrollment in special education services will also not be an exclusionary
        criteria as work by this research group has found that such services do not affect response
        to ADHD treatments (Niemic, Fabiano, Pelham, &amp; Fuller, 2002).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James G Waxmonsky</last_name>
    <role>Principal Investigator</role>
    <affiliation>SUNY Buffalo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel A Waschbusch</last_name>
    <role>Principal Investigator</role>
    <affiliation>SUNY Buffalo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cennter for Children and Families</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>June 9, 2009</study_first_submitted>
  <study_first_submitted_qc>June 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2009</study_first_posted>
  <results_first_submitted>March 23, 2011</results_first_submitted>
  <results_first_submitted_qc>March 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 7, 2020</results_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>Atomoxetine</keyword>
  <keyword>Behavior Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from schools, pediatric offices and the local community through radio and print advertisement. Subjects were recruited between Jan of 2007 and the spring of 2008.</recruitment_details>
      <pre_assignment_details>uneven number because set of twins randomized as one unit at parental request</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Combined Therapy</title>
          <description>atomoxetine plus behavior therapy</description>
        </group>
        <group group_id="P2">
          <title>Drug Therapy</title>
          <description>atomoxetine alone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combined Therapy</title>
          <description>atomoxetine plus behavior therapy</description>
        </group>
        <group group_id="B2">
          <title>Drug Therapy</title>
          <description>atomoxetine alone</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.3" spread="1.6"/>
                    <measurement group_id="B2" value="8.9" spread="1.5"/>
                    <measurement group_id="B3" value="8.59" spread="1.581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rule Violations During Direct Classroom Observation at Endpoint (Week 8)</title>
        <description>Observations were conducted using the Student Behavior Teacher Response Observation Code. After learning the classroom rules, observers watched children in their classrooms for 30 minutes during an academic activity and recorded each time the subject violated a classroom rule. Total classroom rule violations were used as the primary outcome measures for the study.</description>
        <time_frame>Endpoint (Week 8)</time_frame>
        <population>all subjects analyzed using ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Therapy</title>
            <description>atomoxetine plus behavior therapy</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy</title>
            <description>atomoxetine alone</description>
          </group>
        </group_list>
        <measure>
          <title>Rule Violations During Direct Classroom Observation at Endpoint (Week 8)</title>
          <description>Observations were conducted using the Student Behavior Teacher Response Observation Code. After learning the classroom rules, observers watched children in their classrooms for 30 minutes during an academic activity and recorded each time the subject violated a classroom rule. Total classroom rule violations were used as the primary outcome measures for the study.</description>
          <population>all subjects analyzed using ITT</population>
          <units>number occurences per 30 mins</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.15" spread="1.37"/>
                    <measurement group_id="O2" value="4.93" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <p_value_desc>Also tested marginal effects defined as p &lt; .10.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Tukey-Kramer adjustments for post-hoc differences of least squares comparisons</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.93</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impairment Rating Scale (Parent Completed) at Endpoint</title>
        <description>The IRS is a 8 item measure that uses visual-analogue scales to evaluate the child's problem level and need for treatment in developmentally important areas, such as peer relationships, adult-child relationships, academic performance, and classroom behavior 51. The scale is scored from 0 (no problem) to 6 (extreme problem). The scale has excellent test-retest and inter-rater reliability and well supported validity 51, 52.</description>
        <time_frame>Endpoint (Week 8)</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Therapy</title>
            <description>atomoxetine plus behavior therapy</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy</title>
            <description>atomoxetine alone</description>
          </group>
        </group_list>
        <measure>
          <title>Impairment Rating Scale (Parent Completed) at Endpoint</title>
          <description>The IRS is a 8 item measure that uses visual-analogue scales to evaluate the child's problem level and need for treatment in developmentally important areas, such as peer relationships, adult-child relationships, academic performance, and classroom behavior 51. The scale is scored from 0 (no problem) to 6 (extreme problem). The scale has excellent test-retest and inter-rater reliability and well supported validity 51, 52.</description>
          <population>Intent to treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" spread=".37"/>
                    <measurement group_id="O2" value="2.84" spread=".36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <p_value_desc>Also examined marginal effects, defined as p&lt;.10</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impairment Rating Scale (Teachers) at Endpoint</title>
        <description>The IRS is a 6 item measure that uses visual-analogue scales to evaluate the child's problem level and need for treatment in developmentally important areas, such as peer relationships, adult-child relationships, academic performance, and classroom behavior. The scale is scored from 0 (no problem) to 6 (extreme problem). The scale has excellent test-retest and inter-rater reliability and well supported validity.</description>
        <time_frame>Endpoint (Week 8)</time_frame>
        <population>ITT was used</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Therapy</title>
            <description>atomoxetine plus behavior therapy</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy</title>
            <description>atomoxetine alone</description>
          </group>
        </group_list>
        <measure>
          <title>Impairment Rating Scale (Teachers) at Endpoint</title>
          <description>The IRS is a 6 item measure that uses visual-analogue scales to evaluate the child's problem level and need for treatment in developmentally important areas, such as peer relationships, adult-child relationships, academic performance, and classroom behavior. The scale is scored from 0 (no problem) to 6 (extreme problem). The scale has excellent test-retest and inter-rater reliability and well supported validity.</description>
          <population>ITT was used</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" spread="0.42"/>
                    <measurement group_id="O2" value="2.29" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <p_value_desc>Also tested marginal effects defined as p&lt;.10</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.60</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pittsburgh Side Effects Rating Scale (PSERS)(Parent Completed) at Endpoint:</title>
        <description>The PSERS measures adverse events commonly associated with stimulant medication and has been used in multiple studies of ADHD. For this study, the PSERS was modified to also assess adverse emotional events potentially associated with ATX, including suicidal statements. The resulting scale consisted of 14 items (an additional sleep item for parents) rated from 0 (&quot;none&quot;) to 3 (&quot;severe&quot;). An overall side effects score was computed by averaging across all ratings and used in analyses.</description>
        <time_frame>Endpoint (Week 8)</time_frame>
        <population>ITT was used</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Therapy</title>
            <description>atomoxetine plus behavior therapy</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy</title>
            <description>atomoxetine alone</description>
          </group>
        </group_list>
        <measure>
          <title>Pittsburgh Side Effects Rating Scale (PSERS)(Parent Completed) at Endpoint:</title>
          <description>The PSERS measures adverse events commonly associated with stimulant medication and has been used in multiple studies of ADHD. For this study, the PSERS was modified to also assess adverse emotional events potentially associated with ATX, including suicidal statements. The resulting scale consisted of 14 items (an additional sleep item for parents) rated from 0 (&quot;none&quot;) to 3 (&quot;severe&quot;). An overall side effects score was computed by averaging across all ratings and used in analyses.</description>
          <population>ITT was used</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".38" spread=".06"/>
                    <measurement group_id="O2" value=".34" spread=".06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <p_value_desc>Also estimated marginal effects defined as p&lt;.10</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pittsburgh Side Effects Rating Scale (PSERS)(Teacher Rated):</title>
        <description>The PSERS measures adverse events commonly associated with stimulant medication and has been used in multiple studies of ADHD. For this study, the PSERS was modified to also assess adverse emotional events potentially associated with ATX, including suicidal statements. The resulting scale consisted of 13 items (for teachers) rated from 0 (&quot;none&quot;) to 3 (&quot;severe&quot;). An overall side effects score was computed by averaging across all ratings and used in analyses.</description>
        <time_frame>at weeks 8 (Endpoint)</time_frame>
        <population>ITT was used</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Therapy</title>
            <description>atomoxetine plus behavior therapy</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy</title>
            <description>atomoxetine alone</description>
          </group>
        </group_list>
        <measure>
          <title>Pittsburgh Side Effects Rating Scale (PSERS)(Teacher Rated):</title>
          <description>The PSERS measures adverse events commonly associated with stimulant medication and has been used in multiple studies of ADHD. For this study, the PSERS was modified to also assess adverse emotional events potentially associated with ATX, including suicidal statements. The resulting scale consisted of 13 items (for teachers) rated from 0 (&quot;none&quot;) to 3 (&quot;severe&quot;). An overall side effects score was computed by averaging across all ratings and used in analyses.</description>
          <population>ITT was used</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".23" spread=".05"/>
                    <measurement group_id="O2" value=".21" spread=".05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <p_value_desc>also tested marginal effects defined as p&lt;.10</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disruptive Behavior Disorders Rating Scale ODD Subscale (DBD- Parent Completed) at Endpoint</title>
        <description>The DBD consists of 8 items that are the DSM-IV symptoms of Oppositional Defiant Disorder (ODD). Items on the DBD were rated by parents and teachers using Likert scales that ranged from 0 (&quot;not at all&quot;) to 3 (&quot;very much&quot;). The factor structure, reliability and validity of the DBD have been supported in multiple studies.</description>
        <time_frame>Endpoint (Week 8)</time_frame>
        <population>ITT was used</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Therapy</title>
            <description>atomoxetine plus behavior therapy</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy</title>
            <description>atomoxetine alone</description>
          </group>
        </group_list>
        <measure>
          <title>Disruptive Behavior Disorders Rating Scale ODD Subscale (DBD- Parent Completed) at Endpoint</title>
          <description>The DBD consists of 8 items that are the DSM-IV symptoms of Oppositional Defiant Disorder (ODD). Items on the DBD were rated by parents and teachers using Likert scales that ranged from 0 (&quot;not at all&quot;) to 3 (&quot;very much&quot;). The factor structure, reliability and validity of the DBD have been supported in multiple studies.</description>
          <population>ITT was used</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".90" spread=".13"/>
                    <measurement group_id="O2" value="1.12" spread=".13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&gt;.05</p_value>
            <p_value_desc>Also tested marginal effects defined as p&lt;.10</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disruptive Behavior Disorder Rating Scale ODD Subscale(DBD- Teacher Completed) at Endpoint</title>
        <description>The DBD consists of 8 items that are the DSM-IV symptoms of Oppositional Defiant Disorder (ODD). Items on the DBD were rated by parents and teachers using Likert scales that ranged from 0 (&quot;not at all&quot;) to 3 (&quot;very much&quot;). The factor structure, reliability and validity of the DBD have been supported in multiple studies.</description>
        <time_frame>Endpoint (Week 8)</time_frame>
        <population>ITT was used</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Therapy</title>
            <description>atomoxetine plus behavior therapy</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy</title>
            <description>atomoxetine alone</description>
          </group>
        </group_list>
        <measure>
          <title>Disruptive Behavior Disorder Rating Scale ODD Subscale(DBD- Teacher Completed) at Endpoint</title>
          <description>The DBD consists of 8 items that are the DSM-IV symptoms of Oppositional Defiant Disorder (ODD). Items on the DBD were rated by parents and teachers using Likert scales that ranged from 0 (&quot;not at all&quot;) to 3 (&quot;very much&quot;). The factor structure, reliability and validity of the DBD have been supported in multiple studies.</description>
          <population>ITT was used</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".54" spread=".15"/>
                    <measurement group_id="O2" value=".71" spread=".14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <p_value_desc>Also tested marginal effects (p&lt;.10)</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Social Skills Rating Scale Problem Behavior Subscale(SSRS Parent) at Endpoint</title>
        <description>completed by parents to measure children's problem behaviors (PB). Items are rated from 0 (&quot;not at all&quot;) to 2 (&quot;very often&quot;). The scale has 55 items. The score reported below is the sum total of the items on the scale and then averaged for the whole group. Therefore, the range can be between 0 and 110. A higher score indicates a better outcome.</description>
        <time_frame>Endpoint (Week 8)</time_frame>
        <population>ITT was used</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Therapy</title>
            <description>atomoxetine plus behavior therapy</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy</title>
            <description>atomoxetine alone</description>
          </group>
        </group_list>
        <measure>
          <title>Social Skills Rating Scale Problem Behavior Subscale(SSRS Parent) at Endpoint</title>
          <description>completed by parents to measure children's problem behaviors (PB). Items are rated from 0 (&quot;not at all&quot;) to 2 (&quot;very often&quot;). The scale has 55 items. The score reported below is the sum total of the items on the scale and then averaged for the whole group. Therefore, the range can be between 0 and 110. A higher score indicates a better outcome.</description>
          <population>ITT was used</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.48" spread="1.21"/>
                    <measurement group_id="O2" value="19.53" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Also tested marginal effects (p&lt;.10)</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.70</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Social Skills Rating Scale Problem Behavior Subscale(SSRS Teachers) at Endpoint</title>
        <description>The SSRS was completed by teachers to measure children's problem behaviors (PB). Items are rated from 0 (&quot;not at all&quot;) to 2 (&quot;very often&quot;). The scale has 55 items. The score reported below is the sum total of the items on the scale and then averaged for the whole group. Therefore, the range can be between 0 and 110. A higher score indicates a better outcome.</description>
        <time_frame>Endpoint (Week 8)</time_frame>
        <population>ITT was used</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Therapy</title>
            <description>atomoxetine plus behavior therapy</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy</title>
            <description>atomoxetine alone</description>
          </group>
        </group_list>
        <measure>
          <title>Social Skills Rating Scale Problem Behavior Subscale(SSRS Teachers) at Endpoint</title>
          <description>The SSRS was completed by teachers to measure children's problem behaviors (PB). Items are rated from 0 (&quot;not at all&quot;) to 2 (&quot;very often&quot;). The scale has 55 items. The score reported below is the sum total of the items on the scale and then averaged for the whole group. Therefore, the range can be between 0 and 110. A higher score indicates a better outcome.</description>
          <population>ITT was used</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.88" spread="1.25"/>
                    <measurement group_id="O2" value="13.96" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <p_value_desc>Also tested marginal effects (p&lt;.10)</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.80</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADHD Subscale of the DBD (Parent Completed) at Endpoint</title>
        <description>The DBD consists of 18 items that are the DSM-IV symptoms of ADHD. Items on the DBD were rated by parents and teachers using Likert scales that ranged from 0 (&quot;not at all&quot;) to 3 (&quot;very much&quot;). The factor structure, reliability and validity of the DBD have been supported in multiple studies.</description>
        <time_frame>Endpoint (Week 8)</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Therapy</title>
            <description>atomoxetine plus behavior therapy</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy</title>
            <description>atomoxetine alone</description>
          </group>
        </group_list>
        <measure>
          <title>ADHD Subscale of the DBD (Parent Completed) at Endpoint</title>
          <description>The DBD consists of 18 items that are the DSM-IV symptoms of ADHD. Items on the DBD were rated by parents and teachers using Likert scales that ranged from 0 (&quot;not at all&quot;) to 3 (&quot;very much&quot;). The factor structure, reliability and validity of the DBD have been supported in multiple studies.</description>
          <population>Intent to treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="0.11"/>
                    <measurement group_id="O2" value="1.47" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <p_value_desc>Also tested marginal effect (p&lt;.10)</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADHD Subscale of the DBD (Teacher Completed) at Endpoint</title>
        <description>The ADHD subscale of the DBD consists of 18 items that are the DSM-IV symptoms of ADHD. Items on the DBD were rated by parents and teachers using Likert scales that ranged from 0 (&quot;not at all&quot;) to 3 (&quot;very much&quot;). The factor structure, reliability and validity of the DBD have been supported in multiple studies.</description>
        <time_frame>Endpoint (Week 8)</time_frame>
        <population>ITT used</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Therapy</title>
            <description>atomoxetine plus behavior therapy</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy</title>
            <description>atomoxetine alone</description>
          </group>
        </group_list>
        <measure>
          <title>ADHD Subscale of the DBD (Teacher Completed) at Endpoint</title>
          <description>The ADHD subscale of the DBD consists of 18 items that are the DSM-IV symptoms of ADHD. Items on the DBD were rated by parents and teachers using Likert scales that ranged from 0 (&quot;not at all&quot;) to 3 (&quot;very much&quot;). The factor structure, reliability and validity of the DBD have been supported in multiple studies.</description>
          <population>ITT used</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="0.13"/>
                    <measurement group_id="O2" value="1.13" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <p_value_desc>Also tested marginal effects (p&lt;.10)</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The Pittsburgh Side Effect Rating Scale (PSERS) measures adverse events commonly associated with ADHD medication rated from 0 (none) to 3 (severe). Both teachers and parents completed it at weeks 1, 3 and 8.</time_frame>
      <desc>Because of concerns over adverse emotional reactions with three specific items were examined separate from the total score: (1) suicidal statements (e.g., I wish I was dead); (2) crabby/irritable; and (3) tearful, sad, depressed. In addition, weight, height and resting blood pressure were monitored at each office visit (weeks 0, 3 and 8).</desc>
      <group_list>
        <group group_id="E1">
          <title>Combined Therapy</title>
          <description>atomoxetine plus behavior therapy</description>
        </group>
        <group group_id="E2">
          <title>Drug Therapy</title>
          <description>atomoxetine alone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>stomachaches</sub_title>
                <description>computed from combined PSESR ratings from parents and teachers at weeks 1, 3 and 8</description>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="29"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>appetite loss</sub_title>
                <description>computed from combined PSESR ratings from parents and teachers at weeks 1, 3 and 8</description>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headaches</sub_title>
                <description>computed from combined PSESR ratings from parents and teachers at weeks 1, 3 and 8</description>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>motor tics</sub_title>
                <description>computed from combined PSESR ratings from parents and teachers at weeks 1, 3 and 8</description>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Trouble Sleeping</sub_title>
                <description>computed from combined PSESR ratings from parents and teachers at weeks 1, 3 and 8</description>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>picking at skin</sub_title>
                <description>computed from combined PSESR ratings from parents and teachers at weeks 1, 3 and 8</description>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E2" events="17" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>anxiety</sub_title>
                <description>computed from combined PSESR ratings from parents and teachers at weeks 1, 3 and 8</description>
                <counts group_id="E1" events="18" subjects_affected="10" subjects_at_risk="29"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>dulled/tired looking</sub_title>
                <description>computed from combined PSESR ratings from parents and teachers at weeks 1, 3 and 8</description>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="29"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>crabby/irritable</sub_title>
                <description>computed from combined PSESR ratings from parents and teachers at weeks 1, 3 and 8</description>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="29"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>depressed mood/crying episodes</sub_title>
                <description>computed from PSERS ratings from parents &amp; teachers at weeks 1,3+8; there were 2 cases (1 per group)of expressed suicidal ideation; these 2 subjects were assessed by study doctors; neither were found to have a genuine desire to commit suicide.</description>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="29"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>withdrawn from others</sub_title>
                <description>computed from combined PSESR ratings from parents and teachers at weeks 1, 3 and 8</description>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The primary limitation of this study was the lack of a control condition, thereby limiting our ability to detect the causality of observed improvements. Study may not have had sufficient subjects to detect group differences on secondary measures.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>James Waxmonsky M.D.</name_or_title>
      <organization>SUNY Buffalo</organization>
      <phone>305 348 3258</phone>
      <email>jwaxmons@fiu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

